US-EU Working Group on Jobs and Growth: BIO Submits Comments on IP


Development of the Joint Strategic Plan on Intellectual Property Enforcement: BIO Comments


IP Attache Program: BIO's Congressional Hearing Comments

The U.S. Intellectual Property Rights Attaché Program has had significant success and holds immense promise in helping to enhance IP protection abroad for U.S. interests.

Intellectual Property Encourages Collaboration, R&D in Developing Economies

The Biotechnology Industry Organization(BIO) unveiled a report on the role of intellectual property rights in encouraging upstream research and development as well as downstream commercialization of biotechnology at the 2012 BIO International Convention.

Scientific American to Host BIO International Convention Super Session to Release 4th Annual Worldview Report and Scorecard Highlighting Emerging Markets

The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."

International Patent Issues Highlighted at House Judiciary Committee Hearing: BIO Submits Biotech's Challenges


Ron Cohen, President and CEO, Acorda Therapeutics, Inc.

Dr. Cohen discusses the plight of today's emerging biotech companies, and how the federal government can best support innovation within the industry.

2012 Special 301 Report: Biotech's International IP Issues

BIO has identified the following countries of interest and recommends the following for our 2011 Special 301 submission.

China Compulsory License Proposed Provisions Draw Reaction from BIO

BIO's members appreciate the recognition by the Chinese government that robust patent protections will incentivize an innovative biotechnology sector in China.  However, this can only be achieved with policies that ensure rare and narrow use of compulsory licenses only in extreme circumstances.

China Patent Enforcement Comments to USPTO

The importance of intellectual property protection is now understood in China.  However, it appears as though the IP laws are implemented and enforced in ways that benefit Chinese companies over foreign companies.  If China aims to be a leader in biotechnology it needs to understand that intellectual property protections are fundamental for creating an enabling environment for biotechnology.  In this regard, China has yet far to go.